This is the most comprehensive update of basic and clinical information available on mental, addictive and various neurological disorders. Virtually every basic and clinical scientific methodology that is relevant to our understanding and management of brain-related diseases is included in this volume. Readers will find up-to-the-minute studies in functional brain imaging, including MRI and EEG/ERP mapping, the latest application of molecular biology and genetics to solve clinical problems, as well as recent findings on schizophrenia, Alzheimer's disease, drug addiction and alcoholism, suicide and mood disorders. A unique feature of this publication are the nine chapters which examine chronic subsyndromal states in mood, anxiety, and neurocognitive disorders, including chronic fatigue syndrome, conditions which plague so many people worldwide. Other more specific sections of the book deal with antiglutamatergic drugs, the modern treatment of social phobia and characteristics of new atypical neuroleptic drugs. Clinicians who wish to practice at the forefront in their field and researchers requiring up-to-date data will find this book a worthwhile addition to their libraries. Students will also find it a useful and comprehensive reference source.
Preface xi Clinical and Public Health Significance of Chronic Subsyndromal States: Mental Disorders or Normal Variations? 1(53) Diagnosis and Classification of Neurasthenia 1(5) Sartorius, N. (Geneva) The Role of Subsyndromal Depressive Symptoms in Unipolar Major Depression 6(5) Judd, L. L. Paulus, M. Akiskal, H. S. Rapaport, M. H. Kunovac, J. L. (La Jolla/San Diego, Calif) Diagnosis and Treatment of Subsyndromal Seasonal Affective Disorder 11(10) Kasper, S. Praschak-Rieder, N. (Vienna) Chronic Fatigue Syndrome 21(8) Wessely, S. (London) Chronic Disturbances of Temperament 29(4) Akiskal, H. S. (La Jolla, Calif.) Recurrent Brief Psychiatric Syndromes: Hypomania, Depression, Anxiety and Neurasthenia 33(6) Angst, J. (Zurich) Milder Depressive Chronicity: An Important Clinical Problem 39(5) Paykel, E. S. (Cambridge) Mild Neurocognitive Disorder 44(10) Grant, I. (San Diego, Calif.) Applications of Functional Brain Imaging to Solve Clinical Problems 54(14) Visualizing the Living Human Brain. The Techniques and Promise of EEG and Event-Related Potentials Mapping 54(9) Saletu, B. (Vienna) Visualizing the Living Human Brain. The Technique and Promise of Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy 63(5) Mann, K. Bartels, M. (Tubingen) Applications of Molecular Biology and Genetics to Solve Clinical Problems 68(37) The `Novel Dopamine Receptors: Psychiatric Implications 68(7) Schwartz, J.-Ch. Sokoloff, P. (Paris) Multiple Receptor Subtypes: The Impact of Molecular Biology on Pharmacology and Drug Discovery 75(7) Langer, S. Z. (Bagneux) Contributions of Molecular Genetics to the Understanding of Bipolar Depression 82(7) Mendlewicz, J. Souery, D. (Brussels) The Genetics of Schizophrenia 89(16) Cardno, A. G. Murphy, K. C. McGuffin, P. (Cardiff) New Frontiers in Clinical Science: Schizophrenia 105(10) Developmental Malformations in Cerebral Structures of Schizophrenic Patients 105(6) Beckmann, H. (Wurzburg) Cerebral Asymmetry, Language and Psychosis 111(4) Crow, T. J. (Oxford) New Frontiers in Clinical Science: Alzheimers Disease 115(21) Genetics of the Alzheimer Diseases 115(4) Roses, A. D. (Durham, N.C.) Apolipoprotein E and Neurofibrillary Tangles in Alzheimers Disease 119(4) Ohm, T. G. (Berlin) Scharnagl, H. Marz, W. (Freiburg) The Amplifying Effect of XXX-Amyloid on Cellular Calcium Signalling in Alzheimers Disease 123(5) Muller, W. E. Eckert, A. Hartmann, H. Forstl, H. (Mannheim) Prospective Genetic Epidemiology of Dementia in the Very Old 128(8) Altstiel, L. D. (New York, N.Y./Indianapolis, Ind.) Greenberg, D. Lantz, M. Lebow, L. Marin, D. Zhou, G. L. Keddache, M. Yang, X. -P. Mohs, R. (New York, N.Y.) New Frontiers in Clinical Science: Alcoholism and Drug Addiction 136(26) Craving in Alcohol Dependence: Pharmaceutical Interventions 136(12) Lesch, O. M. Benda, N. Gutierrez, K. Walter, H.;(Kalksburg) Sardinian Alcohol-Preferring Rats: An Animal Model of Alcoholism 148(2) Colombo, G. Agabio, R. Balakievskaia, N. Lobina, C. Reali, R. Fadda, F. Gessa, G. L. (Cagliari) Preclinical Effects of Drugs of Abuse 150(3) Sulcova, A. (Brno) Opioid Receptor Heterogeneity: The Use of New Ligands 153(2) Marki, A. (Szeged) Hosztafi, S. (Tiszavasvari) Otvos, F. (Szeged) Schmidhammer, H. (Innsbruck) Toth, G. Borsodi, A. (Szeged) Biological Factors Modulating Drug Reward 155(7) Zvartau, E. Kuzmin, A. Patkina, N. Semenova, S. Bespalov, A. Vekovischeva, O. (St. Petersburg) New Frontiers in Clinical Science: Suicide and Mood Disorders 162(13) Current Concepts of Mechanisms of Action of Antidepressant Treatments Based on Preclinical Studies 162(6) Vetulani, J. (Cracow) Clinical and Neurobiological Risk Factors for Suicidal Behavior 168(3) Mann, J. J. Malone, K. M. Underwood, M. D. Arango, V. (New York, N.Y.) Studies of Suicide and Suicidal Behavior in Hungary 171(4) Rihmer, Z. (Budapest) New Aspects of the Calcium Channel Blocker and Antiglutamatergic Drug, Caroverine 175(26) Which Phencyclidine-Like N-Methyl-D-Aspartate Receptor Antagonists Are Currently Available for Clinical Use? 175(6) Kornhuber, J. (Gottingen) Weller, M. (Tubingen) Riederer, P. (Wurzburg) Caroverine Depresses the Activity of Cochlear Glutamate Receptors (in vivo Model for Drug-Induced Neuroprotection) 181(3) Ehrenberger, K. (Vienna) Felix, D. (Berne) Central Effects of Acute, Intravenous and Oral Caroverine in Man: Double-Blind, Placebo-Controlled EEG Mapping and Psychometry 184(6) Saletu, B. Grunberger, J. Anderer, P. Linzmayer, L. (Vienna) On the Cerebro-Protective Effects of Caroverine: Double-Blind, Placebo-Controlled, EEG Mapping and Psychometric Studies under Hypoxia 190(5) Anderer, P. Saletu, B. (Vienna) Caroverine, a Well-Known Drug with Glutamatergic Effects and New Therapeutic Possibilities 195(3) Konig, P. Bieberschulte, W. (Rankweil) Caroverine in the Therapy of Cochlear-Synaptic Tinnitus: A Placebo-Controlled Blind Study 198(3) Denk, D. -M. Ehrenberger, K. (Vienna) New Developments in Social Phobia 201(11) Epidemiology of Social Phobia 201(4) Lepine, J. -P. Pelissolo, A. (Paris) Psychological Treatment of Social Phobia 205(4) Clark, D. M. (Oxford) Quality of Life in Social Phobia 209(3) Katschnig, H. (Vienna) New Aspects of Atypical Neuroleptics 212(20) Adverse Effects of Atypical Antipsychotics 212(7) Fleischhacker, W. W. Hummer, M. (Innsbruck) Effects of Atypical Antipsychotics on Polysomnograpic Measures in Schizophrenia 219(4) Tandon, R. (Ann Arbor, Mich.) Neurophysiological Aspects of Positive and Negative Schizophrenia and Therapeutic Consequences: Trials with Benzamides 223(9) Saletu, B. Anderer, P. Grunberger, J. Kufferle, B. (Vienna) Selegiline in Alzheimers Disease 232(9) Treatment Strategies in Alzheimers Disease 232(3) Tariska, P. (Budapest) Possible Benefits of a Combination of Selegiline and Cholinesterase Inhibitors 235(3) Schneider, L. S. Olin, J. T. Pawluczyk, S. (Los Angeles, Calif.) Selegiline Slows Down the Decline of Cognitive and Electrophysiological Functions in Alzheimers Disease 238(3) Filip, V. David, I. Klaschka, J. Kolibas, E. (Prague) Tiapridal 241(6) The Pharmacological Properties of Tiapride 241(3) Sanger, D. J. Perrault, G. Schoemaker, H. Scatton, B. (Bagneux) Sensory Aspects in Tic Disorders 244(3) Rothenberger, A. (Gottingen) Teaching of Psychopharmacology 247(3) Teaching Psychopharmacology in Central and Eastern Europe 247(3) Halbreich, U. (Buffalo, N.Y.) Author Index 250(2) Subject Index 252
Biežāk uzdotie jautājumi par e-grāmatām